Go Deep
First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,791 | -6.7 | 6.71 | 0.03 | 3,017.00 |
| Oct 2026 | 17,285 | -7.2 | 7.22 | 0.03 | 3,240.56 |
| Oct 2026 | 16,892 | -7.7 | 7.63 | 0.03 | 3,422.40 |
| Oct 2026 | 17,217 | -7.3 | 7.29 | 0.03 | 3,263.88 |
| Oct 2026 | 16,840 | -7.7 | 7.68 | 0.03 | 3,439.94 |
| Oct 2026 | 15,815 | -8.8 | 8.73 | 0.03 | 3,911.18 |
| Oct 2026 | 15,502 | -9.1 | 9.05 | 0.03 | 4,045.28 |
| Oct 2026 | 15,426 | -9.2 | 9.13 | 0.03 | 4,072.02 |
| Oct 2026 | 15,238 | -9.4 | 9.32 | 0.03 | 4,175.15 |
First Tracks Biotherapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -33,374,000.0 | -50,484,000.0 | -42,445,000.0 | -47,196,000.0 |
| EPS | -0.9 | -1.5 | -1.2 | -1.4 |
First Tracks Biotherapeutics, Inc. Revenue & Profit: Last 2 Years
| Line Item | Dec 2024 | Dec 2023 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net Profit | -163,705,000.0 | -106,150,000.0 |
| EPS | — | -3.1 |
First Tracks Biotherapeutics, Inc. Balance Sheet
| Line Item | Dec 2024 | Dec 2023 |
|---|---|---|
| Total Assets | 441,891,000.0 | 444,109,000.0 |
| Total Liabilities | 50,295,000.0 | 34,260,000.0 |
| Total Equity | 391,596,000.0 | 409,849,000.0 |
Owes vs Owns
First Tracks Biotherapeutics, Inc. owed $0.08 for every $1 it owned in Jun 2026, about the same as $0.08 in Dec 2023.
| Period | Jun 2026 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Owes vs Owns | 0.08× | 0.11× | 0.08× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
First Tracks Biotherapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2024
Cash & short-term investments 87.2%Fixed assets (tangible) 3.7%Long-term investments 8.0%Other assets 1.1%
How it's funded — Dec 2024
Long-term debt 3.2%Payables 0.9%Other liabilities 6.9%Shareholders' equity 88.6%
| Line Item | Dec 2024 | Dec 2023 |
|---|---|---|
| Assets | ||
| Cash & short-term investments | 385.4 | 390.9 |
| Receivables | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 |
| Fixed assets (tangible) | 16.2 | 18.3 |
| Intangible assets | 0.0 | 0.0 |
| Long-term investments | 35.5 | 27.0 |
| Other assets | 4.8 | 7.9 |
| Liabilities & equity | ||
| Short-term debt | 1.9 | 1.8 |
| Long-term debt | 14.1 | 16.0 |
| Payables | 3.8 | 2.4 |
| Other liabilities | 30.5 | 14.0 |
| Shareholders' equity | 391.6 | 409.8 |
| Net tangible assets | 391.6 | 409.8 |
First Tracks Biotherapeutics, Inc. Cash Flow
| Line Item | Dec 2024 | Dec 2023 |
|---|---|---|
| Operating Activities | -125,806,000.0 | -93,004,000.0 |
| Investing Activities | 95,398,000.0 | 144,754,000.0 |
| Financing Activities | 117,523,000.0 | -87,093,000.0 |